About
Takeda Ventures (TVI) is the corporate investment arm of Takeda Pharmaceuticals. It invests in current and future areas of interest for Takeda Pharmaceuticals. As a strategic investor, TVI aims to provide support and guidance to entrepreneurs and early-stage companies driving concepts through clinical proof of concept. Takeda Ventures also strives to forge active, collaborative interactions that result in synergies with Takeda's considerable R&D resources. Takeda Ventures focuses on high-caliber therapeutic and platform based opportunities around the world. It invests in early-stage opportunities that complement Takedas pipeline and products. TVI's mission is to create strategic growth opportunities for Takeda by investing and nurturing Innovative Life Science Companies in areas aligned with Takedas R&D focuses which include; Oncology, Gastroenterology, Neuroscience, and Rare Disease. TVI's aim is to access and support therapeutic and platform innovation working closely with academic innovator, entrepreneurs and investors. It invest in seeds or syndicated venture investing providing to the companies access to the resources of a multinational pharmaceutical company.
Portfolio
Investor Intelligence Q&A
Structured intelligence from startupim data — optimized for AI retrieval and grounding.
- What is Takeda Ventures' primary investment focus?
- Takeda Ventures (TVI) is the corporate investment arm of Takeda Pharmaceuticals, focusing on high-caliber therapeutic and platform-based opportunities globally. It invests in early-stage companies that complement Takeda's pipeline and products, specifically in Oncology, Gastroenterology, Neuroscience, and Rare Disease.
- When was Takeda Ventures founded?
- Takeda Ventures was founded in 2001.
- What is the typical investment stage for Takeda Ventures?
- Takeda Ventures invests in Seed, A Round, and B Round funding stages.
- What is the typical investment amount range for Takeda Ventures?
- Takeda Ventures' investment amounts range from $2.25M to $61M.
- Can you name a notable exit for Takeda Ventures?
- ImmPACT Bio was acquired by Lyell Immunopharma in October 2024. Another notable exit was BiomX, which underwent a Reverse Merger Event in November 2019 and is listed on the NYSE.
- Which sectors does Takeda Ventures concentrate its investments in?
- According to startupim data, Takeda Ventures concentrates all its investments and rounds in the Health Tech & Life Sciences sector.
- Has Takeda Ventures led any investment rounds?
- According to startupim data, Takeda Ventures has not led any investment rounds.
- When was Takeda Ventures' most recent investment activity?
- Takeda Ventures' most recent investment activity was in August 2020, with an investment in ImmPACT Bio.
- Where are Takeda Ventures' main offices located?
- Takeda Ventures has offices in San Diego, California, USA; Chuo City, Tokyo, Japan; and Cambridge, Massachusetts, USA.